CryoCord:
Malaysia’s Premier Stem Cell Banking Company
At CryoCord, we believe in the power of science to safeguard your family’s future. As the premier stem cell company in Malaysia, we utilise revolutionary and secure medical technologies to safeguard your future health.
Founded in 2002, we’ve grown alongside the trust of tens of thousands families in Southeast Asia. They choose CryoCord because of our unwavering commitment to:
Excellence: We ensure the highest standards and service in long-term stem cell cryopreservation.
Expertise: Our team of scientists and healthcare professionals contribute decades of experience to CryoCord.
Our Journey in Numbers:
Building Your Confidence
years of experience
stem cells units stored
consecutive years
– Best Stem Cell Bank
class 100 cleanrooms
1st
in the S.E.A offer CordMSCs storage
1st
in the S.E.A offer CordPSCs-i storage
1st
BSL-2 cGMP facility in Malaysia
cGMP laboratories
Vision
To be Asia’s leader in human cell and gene therapeutics research and development.
Mision Statement
To provide the best possible products and services to its clients by utilising advanced and sophisticated knowledge and skills whilst maintaining a strict code of ethics and professionalism in service delivery.
Service Commitment
To provide the highest quality service to our clients and doctors. Every sample processed by CryoCord is deemed to be of utmost importance; hence, we dedicate our effort to delivering top-quality service without fail.
Core Values
Integrity
There is no compromise when it comes to ethics in our service, whether with our clients, R&D or in the laboratory. We are committed to the highest ethical practice.
Excellence
Always striving to achieve excellence in the name of medical science, CryoCord consists of a passionate team driven to push the boundaries of healthcare.
Innovation
Research and development is not just a part of CryoCord but the foundation of all we do to bring transformative healthcare solutions through biomedical technology.
Our Milestones
2024
- Parenthood Magazine has recognised CryoCord as the Best Stem Cell Bank for the 7th consecutive year.
- For the 13th consecutive year, CryoCord has received the Best Stem Cell Bank Award from Baby Talk Magazine.
2023
- CryoCord has been awarded Best Stem Cell Bank for the 6th consecutive year by Parenthood Magazine.
- CryoCord awarded Best Stem Cell Bank Award by Baby Talk Magazine, for the 12th consecutive year.
2022
- Induced pluripotent stem cells (iPSCs) storage services made available.
- Another CTX license by NPRA, MOH was obtained for perianal fistula clinical trial.
2021
- Collaboration with UM with approval from NPRA on the use of MSC to treat perianal fistula in patients with Crohn’s disease.
- Cytopeutics became the first company in Malaysia to receive CTX license, issued by NPRA, MOH under Akta Jualan Dadah to manufacture stem cells for clinical investigational use.
2020
- CryoCord achieved accreditation by AABB (Association for the Advancement of Blood and Biotherapies).
- First Biosafety Level 2 (BSL-2) cGMP facility built in Malaysia.
- First CAR-T clinical trial approved in Malaysia, in collaboration between Plutonet (a member of the CryoCord Group) and HCTM (UKM).
- Cytopeutics granted with two further USA patents and seven Malaysia patents, including stroke, diabetes, cardiomyopathy, psoriasis, critical limb ischemia, macular oedema and vernal keratoconjunctivitis.
2019
- Cytopeutics became the first stem cell company in the South East Asia awarded with USA patent for MSC treatment for stroke.
- A cGMP certified laboratory was established in Jakarta, Indonesia.
2018
- Cytopeutics initiated multicentre randomised clinical trial using allogeneic UC-MSC approved by MREC, MOH for acute graft-versus-host-disease.
2016
- Cytopeutics became the first stem cell company endorsed by JAKIM as Shariah-Compliant.
- MREC & NSCERT granted the first approval ever for allogeneic UC-MSC clinical trial to Cytopeutics.
2014
- Official collaboration with UKM on stem cell research in retina regeneration.
- Elixir Biotech incorporated to focus on immune cell therapy.
2013
- New Group Corporate Headquarters at Bio-X Centre, Cyberjaya.
- cGMP (PIC/S) state-of-the-art laboratory certification was awarded by NPRA, a division of MOH, Malaysia.
2012
- Induced pluripotent stem cells first established in Professor Dr. Cheong’s laboratory in
UTAR, Sungai Long Campus.
- Acquisition of StemTech International (BioNexus status).
2011
- Cytopeutics became the first company in Malaysia approved to undertake 4 autologous
MSC randomised clinical trials (RCT).
- Cellavie, a wellness company, was established.
- The establishment of CryoCord Jakarta office at Mega Kuningan, Indonesia
2010
- Official collaboration with Universiti Tunku Abdul Rahman on stem cell research.
- Landmark scientific paper by Cytopeutics on first clinical demonstration of myocardial scar tissue resolution following MSC treatment published in Cytotherapy.
2009
- Umbilical cord derived MSC (CordMSCs) storage services launched.
- Awarded ISO 15189 certification by Laboratory Accreditation Scheme of Malaysia.
2008
- Awarded stem cell banking company’s license, under PHFS Act 1998 by MOH, Malaysia.
2007
- Cytopeutics conceived by Emeritus Professor Dr. Cheong Soon Keng, Associate Professor Dr. Chin Sze Piaw, Dr. Then Kong Yong and Mr. James Then, for research into cell-based therapy.
- MSC, chosen to be our main focus for research were first isolated from bone marrow in Professor Dr. Cheong’s laboratory, HUKM, in 2002.
2006
- First successful transplant using cord blood stored by CryoCord for patient diagnosed with leukaemia in Hospital Kuala Lumpur.
- Two landmark research articles on Mesenchymal Stem Cell (MSC) were published in peer reviewed journal, Cytotherapy.
2003
- Awarded ISO 14644 Class 5 (Class 100) Cleanroom and certified to NASA and US Federal Standard 209E for laboratory standards.
2002
- Dr. Then Kong Yong and Professor Dr. Cheong Soon Keng envisioned the concept of the establishment of a stem cell banking company in Malaysia.
- CryoCord was awarded Multimedia Super Corridor status which carry special incentives.